Organon & Co. (NYSE:OGN) to Issue $0.02 Quarterly Dividend

Key Points

• Organon announced a quarterly dividend of $0.02 per share, payable September 10 to shareholders of record on August 14. The dividend equates to $0.08 annually and a yield of approximately 0.6%.
• The dividend appears well covered, with a current payout ratio of 2.0%; analysts expect a future payout ratio of about 2.3% based on projected earnings.
• Organon’s latest quarterly results slightly missed expectations, reporting $0.85 in earnings per share versus the $0.87 consensus and revenue of $1.56 billion versus $1.57 billion expected.

Organon & Co. (NYSE:OGN - Get Free Report) announced a quarterly dividend on Friday, July 31st. Investors of record on Friday, August 14th will be paid a dividend of 0.02 per share on Thursday, September 10th. This represents a c) dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th.

Organon & Co. has a dividend payout ratio of 2.0% meaning its dividend is sufficiently covered by earnings. Analysts expect Organon & Co. to earn $3.44 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.3%.

Organon & Co. Trading Up 0.0%

OGN stock traded up $0.01 during mid-day trading on Friday, reaching $13.55. The company had a trading volume of 2,689,351 shares, compared to its average volume of 6,106,729. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42. The company has a market capitalization of $3.56 billion, a PE ratio of 14.58, a price-to-earnings-growth ratio of 1.25 and a beta of 1.54. The firm has a 50 day moving average of $13.47 and a 200 day moving average of $10.38. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.60.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $0.85 earnings per share for the quarter, missing the consensus estimate of $0.87 by ($0.02). The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. On average, equities analysts predict that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.